SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck

Table 1 Prevalence of PD-L1 expression based on baseline characteristics and HNSCC tumor characteristics

Characteristic, %	N^a	PD-L1 TC ≥ 25% (n = 132)	PD-L1 TC < 25% (n = 264)
Median age, years (range)		62.0 (38.0–87.0)	62.0 (28.0–93.0)
< 60	167	32.9	67.1
≥ 60	228	33.8	66.2
Sex
Male	317	30.9	69.1
Female	79	43.0	57.0
Race
Caucasian	339	32.7	67.3
Black or African American	20	30.0	70.0
Asian	22	50.0	50.0
Region
United States	205	29.3	70.7
Asia	22	50.0	50.0
Europe	169	36.1	63.9
ECOG PS
0	73	50.7	49.3
1	87	32.2	67.8
≥ 2	41	26.8	73.2
Tobacco use
Current	97	26.8	73.2
Former	199	32.2	67.8
Never	78	42.3	57.7
Alcohol consumption
Current	148	26.4	73.6
Former	123	32.5	67.5
HPV status
Positive	37	21.6	78.4
Negative	93	25.8	74.2
Timing of tissue sample extraction
Pre-1st chemotherapy, %	202	30.2	69.8
Post-1st chemotherapy, %	36	25.0	75.0
Type of tumor sample
Surgical resection	186	34.9	65.1
Surgical biopsy	199	32.2	67.8
Punch biopsy	8	12.5	87.5
Location of tumor sample
Primary tumor	153	34.0	66.0
From recurrent disease	175	32.6	67.4
From metastatic disease	80	33.8	66.3
Primary tumor site		132	261
Oral cavity	108	43.5	56.5
Oropharynx	61	34.4	65.6
Hypopharynx	21	9.5	90.5
Larynx	99	30.3	69.7
Overlapping lesion	22	22.7	77.3
Stage at index date^b
Stage 0–III	17	29.4	70.6
Stage IVA	62	37.1	62.9
Stage IVB	21	23.8	76.2
Stage IVC	230	31.3	68.7
Time from diagnosis to index
Median, months (range)		11.4 (0.0–475.9)	14.7 (0.0–349.8)
Sites of new metastases post index date
Local lymph node	89	31.5	68.5
Lung	77	27.3	72.7
Bone	29	37.9	62.1
Distant lymph node	23	34.8	65.2
Liver	23	30.4	69.6
Skin/soft tissue	21	42.9	57.1
Head and neck	11	27.3	72.7
Pleura	9	44.4	55.6

^aPatients with PD-L1 result N = 396
^bIndex date is defined as date of diagnosis of R/M HNSCC not amenable to local therapy
ECOG PS Eastern Cooperative Oncology Group performance status, HNSCC head and neck squamous cell carcinoma, HPV human papilloma virus, mo months, PD-L1 programmed cell death-ligand 1, R/M recurrent and/or metastatic, TC tumor cell

ISSN: 1479-5876